A 922500_959122-11-3_DataSheet_MedChemExpress
QIAGEN Endotoxin Removal Solution说明书
Endotoxin Removal Solution Catalog Number E4274Product DescriptionEndotoxins are lipopolysaccharides (LPS), a major component of the Gram-negative bacterial cell wall, and are commonly found as contaminants in plasmid DNA preparations from E. coli. Endotoxins are large, negatively charged molecules that co-purify with DNA on ion exchange and size exclusion columns and in CsCl banding. Endotoxins are extremely potent stimulators of the mammalian immune system and are toxic to primary cells and to animals. The endotoxin toxicity is an obstacle to in vitro and in vivo transfection experiments.Non-ionic detergents, traditionally used for separation of integral membrane proteins,1 can be utilized for removal of endotoxins from DNA solutions by phase separation.2The solubility behavior of a detergent in a dilute, aqueous solution at physiological salt and pH conditions is strongly dependent upon the temperature of the solution. At low temperatures, the detergent forms a clear, micellar solution, but above the cloud point temperature, the micelles form larger, turbid aggregates and ultimately fuse to form a separate phase. The lower phase is detergent-enriched and the detergent-depleted upper phase contains detergent at a concentration slightly above the critical micellar concentration (CMC). Amphiphilic and hydrophobic molecules associated with the micelles of the detergent will aggregate within the detergent-enriched phase, while the soluble, hydrophilic molecules will remain in the detergent-depleted upper phase.Extraction of endotoxin contaminated DNA solutions with the appropriate non-ionic detergent will separate the hydrophilic DNA from the amphiphilic endotoxin. The amphiphilic endotoxin will associate with the lower phase, while the DNA will remain in the upper, detergent-depleted phase.2Reagents and equipment required, but not provided • Water, Molecular Biology Reagent, Catalog Number W4502• E-TOXATE® Water, Catalog Number 2107, or Tris-EDTA (TE) buffer 100×, Catalog NumberT9285• DNA solution (0.5 ml), ~ 1 mg/ml in E-TOXATE®Water or TE buffer• 3 M sodium acetate solution, pH 7.5.• 2-Propanol, Catalog Number I9516, or Ethanol, 190 proof, Catalog Number E7148; 200 proof, CatalogNumber E7023• 70% Ethanol• E-TOXATE®reagents Kits, Catalog Numbers 210A1, 210B1 or 210C1• Ice bucket• Heat block or incubator at 37 °C• Microcentrifuge at room temperature• 1.5 or 2 ml sterile microcentrifuge tubes• Endotoxin-free pipet tips (40-200 µl, 200-1000 µl) Precautions and DisclaimerThis product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.StorageStore at room temperature.Note: Removal of endotoxins from DNA preparations can be performed either during the final stage of DNApreparation, or during an earlier stage.Procedures for Endotoxin RemovalDuring the final stage of DNA preparationNote: The procedure described below was performed on plasmid DNA produced in E. coli DH5α cells.• Losses of up to 50% of the DNA are expected. • Use of a DNA concentration above therecommended 1 mg/ml reduces the efficiency ofthe procedure.1. Pipette 500 µl of the DNA solution into a sterilemicrocentrifuge tube.2. Add 50 µl of the 3 M sodium acetate solution to theDNA sample.3. Incubate on ice for 5 minutes.4. Add 100 µl of cold Endotoxin Removal Solution.5. Mix thoroughly and incubate on ice for 10 minutes.The solution should be light blue and clear.6. Incubate the tube at 37 °C for 20 to 30 minutes oruntil the phases separate.7. Spin for 5 minutes at 3000 x g in themicrocentrifuge. The upper phase is colorless and clear, while the lower phase is blue.8. Carefully transfer the upper phase containing theDNA to a clean microcentrifuge tube.9. Repeat steps 4 through 8 twice.10. Add 0.6× volume of 2-propanol. Mix by inversion atroom temperature and centrifuge at 15,000 x g for30 minutes at 4 °C. Alternatively, add2.5× volumes of ethanol. Incubate overnight at –20°C or 20 minutes at –70 °C and centrifuge at15,000 x g for 30 minutes at 4 °C.11. Carefully remove the supernatant12. Wash the DNA pellet twice with cold 70% ethanol.Remove the supernatant.13. Air-dry the pellet.14. Suspend the DNA in 100 µl of endotoxin free wateror TE buffer.15. Determine DNA concentration and endotoxin levelsusing endotoxin assay reagents and compare tothe starting material. During an earlier stage of DNA preparationThis procedure is based on the alkaline lysis of E. coli DH5α cells.3 The endotoxins are removed immediately after alkaline cell lysis, neutralization, and a clarification step. The resulting high salt solution is suitable for the endotoxin removal step. It is performed under “endotoxin free” conditions. The plasticware used is either sterile and disposable, or NaOH-treated. The buffers are prepared with endotoxin free water.1. Add the Endotoxin Removal Solution (0.2× volume)to the cold, crude DNA solution.2. Incubate on ice and mix occasionally by inversionto obtain a homogenous, clear blue solution3. Incubate at 37 °C for 20 to 30 minutes until thephase separation is obvious.4. Spin for 5 minutes at low speed (3000 x g) at roomtemperature.5. Transfer the upper aqueous phase to an endotoxinfree container.6. Proceed with the DNA purification by any method.Use endotoxin-free buffers and containers. References1. Bordier, C., J. Biol. Chem., 256, 1604-1607, (1981).2. Cotten, M. et al., Gene Therapy, 1, 239-246,(1994).3. Sambrook et al., Molecular Cloning, a LaboratoryManual, 2nd Ed. p. 1.38RK,PHC 09/05-1Sigma brand products are sold through Sigma-Aldrich, Inc.Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side ofthe invoice or packing slip.。
A_922500_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name : A 922500Catalog No. :HY-10038CAS No. :959122-11-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:DGAT⁻1 Inhibitor 4a; A⁻922500; A922500Formula:C26H24N2O4Molecular Weight:428.48CAS No. :959122-11-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Off-white to orange (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutant.IATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
QIAGEN Perfe CTa qPCR ToughMix UNG ROX 产品说明书
©2018 QIAGEN Beverly, Inc. 100 Cummings Center Suite 407J Beverly, MA 01915 Quantabio brand products are manufactured by QIAGEN Beverly, Inc.Intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease.95139 / IFU-095.1 REV 02PerfeC T a ® qPCR ToughMix ® UNG ROX ™DescriptionPerfeC T a qPCR ToughMix UNG ROX is a 2X concentrated ready-to-use reaction cocktail for PCR amplification of DNA templates that overcomes many known inhibitors of PCR often present in crude samples extracted from environmental specimens, plant tissues, or animal tissues. It is a versatile and robust real-time qPCR reagent that provides maximum sensitivity and PCR efficiency with a variety of fluorogenic probe chemistries, including TaqMan ® hydrolysis probes. PerfeC T a qPCR ToughMix UNG ROX contains all required reaction components, except primers, probe(s), and DNA template. Inclusion of uracil DNA glycosylase (UNG), and substitution of dTTP with dUTP, prevents amplification of carry-over contamination from previous dU-containing PCRs.A key component of PerfeC T a qPCR ToughMix UNG ROX is an ultra pure, highly processive thermostable DNA polymerase that is combined with high avidity monoclonal antibodies. This proprietary polymerase mix is highly resistant to PCR inhibitors and provides an extremely stringent automatic hot-start allowing reaction assembly, and temporary storage, at room temperature prior to PCR amplification. PerfeC T a qPCR ToughMix UNG ROX delivers exceptional performance with either fast or conventional PCR cycling protocols.Instrument CompatibilityDifferent real-time PCR systems employ different strategies for the normalization of fluorescent signals and correction of well-to-well optical variations. It is important to match the appropriate reference dye to each specific optical detection system. PerfeCta qPCR ToughMix, ROX contains an optimal concentration of a stabilized carboxy-X-rhodamine compound (ROX ™) for instruments that use an excitation wavelength of ~490 nm and 605 to 610 nm emission channel for the reference signal. Please consult our Product Finder selection tool at to find the correct product for your real-time PCR system. ComponentsPerfeC T a qPCR ToughMix UNG ROX (2X): 2X concentrated reaction buffer containing optimized concentrations of MgCl 2, dNTPs (dATP, dCTP, dGTP,dUTP), hot-start DNA polymerase, uracil DNA glycosylase (UNG), and stabilizers.Storage and StabilityStore components in a constant temperature freezer at -25°C to -15°C protected from light upon receipt. Repeated freezing and thawing does not impair product performance. After thawing, mix thoroughly before using.For lot specific expiry date, refer to package label, Certificate of Analysis or Product Specification Form.Guidelines for qPCR:▪ The design of highly specific primers and probes is a critical parameter for successful real-time PCR. The use of computer aided primer design programs is encouraged in order to minimize the potential for internal secondary stru cture and complementation at 3’-ends within each primer, the primer pair, and primer/probe combinations. For best results, amplicon size should be limited to 65 - 200 bp. Optimal results may require titration of primer concentration between 100 and 900 nM. A final concentration of 300 - 400 nM each primer and 100 to 250 nM probe is effective for most applications. Increasing the concentration of the primer that initiates synthesis of the target strand that is complementary to the probe can improve fluorescent signal for some primer/probe systems.▪ Preparation of a reaction cocktail is recommended to reduce pipetting errors and maximize assay precision. Assemble the reaction cocktail with all required components except sample template (genomic DNA or cDNA) and dispense equal aliquots into each reaction tube. Add the DNA template to each reaction as the final step. Addition of samples as 2 to 5- L volumes will improve assay precision.▪ Suggested input quantities of template are: cDNA corresponding to 1 pg to 100 ng of total RNA; 10 pg to 1 µg genomic DNA▪ After sealing each reaction, vortex gently to mix contents. Centrifuge briefly to collect components at the bottom of the reaction tube. Reaction AssemblyComponentVolume for 20-μL rxn.Final ConcentrationPerfeC T a qPCR ToughMix UNG ROX (2X) 10 µL 1xForward primer variable 100 – 900 nM Reverse primer variable 100 – 900 nM Probevariable 100 – 250 nMNuclease-free water variable Template2 – 5 µL variable Final Volume (μL)20 µLNote : For smaller or larger reaction volumes scale all components proportionally.Cat No. 95139-250 Size: 250 x 20-uL reactions (2 x 1.25 mL) Store at -25ºC to - 15°C protected from light95139-012 1250 x 20-µL reactions (10 x 1.25 mL)95139-05K5000 x 20-µL reactions (1 x 50 mL)©2018 QIAGEN Beverly, Inc. 100 Cummings Center Suite 407J Beverly, MA 01915 Quantabio brand products are manufactured by QIAGEN Beverly, Inc.Intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease.95139 / IFU-095.1 REV 02PCR Cycling ProtocolFast 2-Step Cycling Fast 3-Step Cycling Standard Cycling UNG carry-over incubation – optional:Initial denaturation: PCR cycling (30-45 cycles):The appropriate step for fluorescent data collection varies for different probe assay formats. Data collection for 5’-nuclease probe assays (TaqMan probe) should be carried out at the end of the extension step. Use the annealing step for data collection with hybridization probe assays (HybProbe ® FRET hybridization probes, Molecular Beacons, Solaris ® qPCR Assays, Scorpions ® primers, etc.).End-point analysis should be carried out at a suitable temperature for your detection probe chemistry.‡ UNG incubation is optional. Alternate protocols are acceptable. We find that a 5 minute incubation at 45ºC is significantly more effective at eliminating carry-over contamination than the more typical procedure of 50ºC for 2 min.* Full activation of the DNA polymerase occurs within 10 seconds at 95ºC; however, optimal initial denaturation time is template dependent and will affect qPCR efficiency and sensitivity. Amplification of genomic DNA or supercoiled plasmid DNA targets may require 5 to 10 min at 95ºC to fully denature and fragment the template. Short double-stranded DNA template (PCR product) or single-stranded DNA template, such as cDNA, may require as little as 1s at 95ºC. Use 30s at 95ºC as a general starting point.† Extension time is dependent upon amplicon length and the minimal data collection time requirement for your qPCR instrument. Use 30s at 60ºC as a general starting point. Some assay designs and/or detection chemistries may require a 3-step cycling protocol for optimal performance. Optimal annealing temperature and time may need to be empirically determined for any given primer set and real-time instrument.Quality ControlKit components are free of contaminating DNase and RNase. PerfeC T a qPCR ToughMix UNG ROX is functionally tested in qPCR. Kinetic analysis must demonstrate linear resolution over six orders of dynamic range (R 2 > 0.990) with a 2-fold discrimination of starting template and a PCR efficiency > 95%.Limited Label LicensesUse of this product signifies the agreement of any purchaser or user of the product to the following terms:1. The product may be used solely in accordance with the protocols provided with the product and this manual and for use with components contained in the kit only. QIAGEN Beverly, Inc. grants no license under any of its intellectual property to use or incorporated the enclosed components of this kit with any components not included within this kit except as described in the protocols provided with the product, this manual, and additional protocols available at Some of these additional protocols have been provided by Quantabio Product users for Quantabio users. These protocols have not been thoroughly tested or optimized by QIAGEN Beverly, Inc.. QIAGEN Beverly, Inc. neither guarantees them nor warrants that they do not infringe the rights of third-parties.2. Other than expressly stated licenses, QIAGEN Beverly, Inc. makes no warranty that this kit and/or its use(s) do not infringe the rights of third-parties.3. This kit and its components are licensed for one-time use and may not be reused, refurbished, or resold.4. QIAGEN Beverly, Inc. Specifically disclaims any other licenses, expressed or implied other than those expressly stated.5. The purchaser and user of the kit agree not to take or permit anyone else to take any steps that could lead to or facilitate any acts prohibited above. QIAGEN Beverly, Inc. may enforce the prohibitions of this Limited License Agreement in any Court, and shall recover all its investigative and Court costs, including attorney fees, in any action to enforce this Limited License Agreement or any of its intellectual property rights relating to the kit and/or its components.This product is licensed under U.S. Patent No. 7,972,828 and corresponding US and foreign patents and patent applications for any use for research and development purposes; the license expressly excludes any use for diagnostic testing or clinical therapeutics in humans or animals.The use of this product is covered by at least one claim of U.S. Patent No. 7,687,247 owned by Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. Commercial Purposes means any activity for which a party receives or is due to receive consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. The buyer cannot use this product or its components or materials made using this product or its components for therapeutic, diagnostic or prophylactic purposes. Further information on purchasing licenses under the above patents may be obtained by contacting the Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008. Email: *************************.PerfeC T a, and ToughMix are registered trademarks of QIAGEN Beverly, Inc.. TaqMan is a registered trademark of Roche Molecular Systems, Inc. HybProbe is a registered trademark of Roche Diagnostics GmbH. ROX is a trademark Life Technologies Corporation. Solaris is a registered trademark of Thermo Fisher Scientific Inc. Scorpions is a registered trademark of DxS, Ltd. of Manchester, UK.。
CAS号1629654-95-0-PD-1_PD-L1 Inhibitor 3基本资料MedBio
包装
纯度
MedBio
MED11227
放线菌素D
Actinomycin D
50-76-0
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11314
R-7050
R-7050
303997-35-5
25mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11245
美法仑
Melphalan
148-82-3
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11231
丝裂霉素c
Mitomycin C
50-07-7
10mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11301
A-1331852
A-1331852
1430844-80-6
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11271
AMG 232
AMG232
1352066-68-2
10mg
≥98%ቤተ መጻሕፍቲ ባይዱ
5mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
CHIR-99021_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:CHIR–99021 is a GSK–3α/β inhibitor with IC 50 of 10 nM/6.7 nM; > 500–fold selectivity for GSK–3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.IC50 & Target: IC50: 10 nM/6.7 nM (GSK–3α/β)[1]In Vitro: CHIR 99021inhibits human GSK–3β with K i values of 9.8 nM [1]. CHIR 99021 is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP–binding sites.In vitro kinase assays reveal that CHIR 99021 specifically inhibits GSK3β (IC 50=~5 nM) and GSK3α (IC 50=~10 nM), with little effect on other kinases [2]. In the presence of CHIR–99021 the viability of the ES–D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM CHIR–99021 with an IC 50 of 4.9μM [3].In Vivo: In ZDF rats, a single oral dose of CHIR 99021 (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3–4 h after administration [1]. CHIR99021 (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). CHIR99021 treatment significantly blocks crypt apoptosis andaccumulation of p–H2AX + cells, and improves crypt regeneration and villus height. CHIR99021 treatment increases Lgr5+ cellsurvival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h [4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[2]Kinases are purified from SF9 cells through use of their His or Glu tag. Glu–tagged proteins are purified, and His–tagged proteins are purified. Kinase assays are performed in 96–well plates with appropriate peptide substrates in a 300–μL reaction buffer (variations on 50 mM Tris–HCl, pH 7.5, 10 mM MgCl 2, 1 mM EGTA, 1 mMdithiothreitol, 25 mMβ–glycerophosphate, 1mM NaF, and 0.01% bovine serum albumin). Peptides has K m values from 1 to 100 μM. CHIR 99021 or CHIR GSKIA is added in 3.5μL of Me 2SO, followed by ATP to a final concentration of 1 μM. After incubation, triplicate 100–μL aliquots are transferred to Combiplate 8 plates containing 100 μL/well of 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with phosphate–buffered saline, filled with 200 μL of scintillation fluid, sealed, and counted in a scintillation counter 30 min later. All of the steps are at room temperature. The percentage of inhibition is calculated as 100×(inhibitor–no enzyme control)/(Me 2SO control–no enzyme control)[2].Cell Assay: CHIR 99021 is dissolved in DMSO and stored, and then diluted with appropriate media before use [3].[3]The viability of the mouse ES cells is determined after exposure to different concentrations of GSK3 inhibitors for three days using the MTT assay.The decrease of MTT activity is a reliable metabolism–based test for quantifying cell viability; this decrease correlates with the loss of cell viability. 2,000 cells are seeded overnight on gelatine–coated 96–well plates in LIF–containing ES cell medium. On the next day the medium is changed to medium devoid of LIF and with reduced serum and supplemented with 0.1–1 μM BIO, or 1–10 μM SB–216763, CHIR–99021 or CHIR–98014. Basal medium without GSK3 inhibitors or DMSO is used as control. All tested conditions are analyzed in triplicates [3].Product Name:CHIR–99021Cat. No.:HY-10182CAS No.:252917-06-9Molecular Formula:C 22H 18Cl 2N 8Molecular Weight:465.34Target:GSK–3; GSK–3; Autophagy Pathway:Stem Cell/Wnt; PI3K/Akt/mTOR; Autophagy Solubility:DMSO: ≥ 5.1 mg/mLAnimal Administration: CHIR 99021 is formulated as solutions in 20 mM citrate–buffered 15% Captisol or as fine suspensions in0.5% carboxymethylcellulose (Rat)[1].CHIR 99021 is prepared in DMSO and diluted (Mice)[4].[1][4]Rat[1]Primary hepatocytes from male Sprague Dawley rats that weighed <140 g are prepared and used 1–3 h after isolation. Aliquotsof 1×106cells in 1 mL of DMEM/F12 medium plus 0.2% BSA and CHIR 99021(orally at 16 or 48 mg/kg) or controls are incubated in 12–well plates on a low–speed shaker for 30 min at 37°C in a CO2–enriched atmosphere, collected by centrifugation and lysed by freeze/thaw in buffer A plus 0.01% NP40; the GS assay is again performed.Mice[4]Mice 6–10 weeks old are used. The PUMA+/+ and PUMA–/– littermates on C57BL/6 background (F10) and Lgr5–EGFP(Lgr5–EGFP–IRES–creERT2) mice are subjected to whole body irradiation (TBI), or abdominal irradiation (ABI). Mice are injected intraperitoneally (i.p.) with 2 mg/kg of CHIR99021 4 h before radiation or 1 mg/kg of SB415286 28 h and 4 h before radiation. Mice are sacrificed to collect small intestines for histology analysis and western blotting. All mice are injected i.p. with 100 mg/kg of BrdU before sacrifice.References:[1]. Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588–95.[2]. Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998–1004.[3]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta–catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.[4]. Wang X, et al. Pharmacologically blocking p53–dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
美迪辛士化学产品清单表说明书
1: Identification of the substance/mixture and of the company/undertaking 1.1 Product identifier Medisanitize Universal Wipes1.2 Relevant identified uses of the substance or mixture and uses advised againstUses:Disinfection of hands and hard surfaces 1.3 Details of the supplier of the Safety Data SheetCompany name Extergeo industries ltdAddress B5 Buckshaw linkBuckshaw villageChorleyPR7 7ELUKTelephone +44(0)1772347771EmailWebsite 1.4 Emergency Telephone Number 017723477712: Hazards identification2.1 Classification of the substance or mixture2.1.1Regulation (EC) No 1272/2008(CLP)Mixture not classified as hazardous2.2 Label elements2.2.1 Label elements Contains PHMB. May produce an allergic reaction.GHS Product Identifier Medisanitize Universal WipesSignal word(s) WarningPrecautionary statement Prevention P102 - Keep out of reach of children. P103 - Read label before use.Precautionary statement: Response P101 - If medical advice is needed, have product container or label at hand.P301+P330+P331: IF SWALLOWED: Rinse mouth.P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.2.3Other hazards Not classified as PBT or vPvB.3: Composition/Information on ingredients3.1 Substances4: First-aid measures4.1Description of first aidInhalationmeasures Move affected person to fresh air at once. When breathing is difficult, properly trained personnel may assist affected person by administering oxygen. Get medical attention.Eye contact Rinse immediately with plenty of water. Remove any contact lenses and openeyelids wide apart. Continue to rinse for at least 15 minutes. Get medical attention if any discomfort continues.Skin contact Remove contaminated clothing immediately and wash skin with soap andwater. Get medical attention if any discomfort continues. Wash contaminated clothing before reuse.IngestionMove affected person to fresh air and keep warm and at rest in a position comfortable for breathing. Rinse mouth thoroughly with water. Give plenty of water to drink. Do not induce vomiting. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention immediately.4.2Most important symptoms and effects, both acute and delayed May cause irritation.5.1 Extinguishing media Suitable extinguishing media for the surrounding fire should be used.5.2Special hazards arising from the substance or mixtureCorrosive. In combustion emits toxic fumes.5.3 Advice for firefighters Standard protective equipment should be worn by fire fighters, inparticular eye / face protection.6: Accidental release measures6.1 Personal precautions, Large spillages are highly unlikely due to pre-saturation of liquid on protectiveequipment and fabric substrate. emergency procedures6.2 Environmental precautions Do not allow product to enter drains. Do not flush into surface water.6.3 Methods and material for Transfer to suitable, labelled containers for disposal. Clean spillagecontainment and cleaning up area thoroughly with plenty of water.6.4 Reference to other sections For recommended personal protective equipment see Section 8. For disposal see Section 13.7: Handling and storage7.1 Precautions for safe handling Avoid contact with eyes. Adopt best Manual Handling considerationswhen handling, carrying and dispensing.7.2 Conditions for safe storage,including any incompatibilities Keep out of the reach of children. Keep in a cool, dry, well ventilated area. Keep containers tightly closed.7.3 Specific end use No relevant information available.8: Exposure controls/personal protection8.1 Control parametersExposure controls No data availableExposure Limit Values No data available8.2 Engineering controlsRespiratory protection Keep in a cool, dry, well ventilated area.Individual protection measures None normally requiredEnvironmental exposure controls None normally required9: Physical and chemical properties9.1 Information on basic physical and chemical propertiesAppearance White nonwoven fabric pre-saturated with a colourlesssolutionOdour SpearmintpH No information available10: Stability and reactivity10.1 Reactivity Stable under normal conditions of storage/use.10.2 Chemical Stability Stable under recommended storage and handling conditions.10.3 Possibility of hazardousNone expectedreactions10.4 Conditions to avoid Avoid excessive heat. Do not allow to freeze.10.5 Incompatible materials Strong acids and Strong bases. Strong oxidising agents.In combustion emits toxic fumes10.6 Hazardous decompositionproducts11: Toxicological informationNo data available for this product12: Ecological informationNo data available for this product13: Disposal considerations13.1 Waste treatment Dispose of as special waste in compliance with local and national regulations.methods Empty containers can be sent to landfill after cleaning, if in compliance with local and national regulations.14: Transport informationThis preparation is not classified as “Hazardous” for transport purposes15: Regulatory information15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture Notapplicable.Chemical Safety Assessment15.2 A chemical safety assessment has not been carried out for the substance or the mixture by the supplier.16: Other informationRevision information:Reviewed – no changesList of Abbreviations used in this SDS:CAS Chemical Abstracts ServiceCLP Classification, Labelling and Packaging Regulation (EC) no 1272/2008EC European Community/CommissionPBT Persistent, Bioaccumulative and ToxicREACH Registration, Evaluation, Authorisation and Restriction of Chemicals Regulation(EC) no 1907/2006vPvB very Persistent, very BioaccumulativeReferencesCLP Regulation 1272/2008ECHA Chem database of registered substancesSuppliers’ SDSR Phrases and H Statements used in Section 3Acute Tox. 4: H312 - Harmful in contact with skinAcute Tox. 4: H302 - Harmful if swallowed.Skin Corr. 1B: H314 - Causes severe skin burns and eye damage.Aquatic Acute 1: H400 - Harmful to aquatic lifeAquatic Chronic 2: H411 - Toxic to aquatic life with long lasting effects Carc.2: H351 - Suspected of causing cancer.Acute Tox. 2: H330 - Fatal if inhaled.STOT RE 1: H372 - Causes damage to organs through prolonged or repeated exposure.Eye Dam. 1: H318 - Causes serious eye damage.Skin Sens. 1B: H317 - May cause an allergic skin reaction.Aquatic Chronic 1: H410 - Very toxic to aquatic life with long lasting effectsTraining requirements for workersNo specific training required for workersThis Safety Data Sheet contains information concerning the potential risks to those involved in handling, transporting, and working with the material, as well as describing potential risks to the consumer and the environment. This information is based on our present state of knowledge and is intended to describe our products from the point of view of the safety requirements. It should not be construed as guaranteeing specific properties. This Safety Data Sheet is prepared in accordance with formatting described in the REACH Regulation (EC) No 1907/2006 and described in CLP Regulation (EC) No 1272/2008.。
UPLC-Q-TOF-MS
第43 卷 第 4 期2024 年4 月Vol.43 No.4511~522分析测试学报FENXI CESHI XUEBAO （Journal of Instrumental Analysis ）UPLC-Q-TOF-MS/MS 法分析鉴定鸡血藤中药复方提取物的化学成分谢灿辉1，贾德政1，胥爱丽2，邬旻珊1，肖观林2，毕晓黎2，张素中3，曹颖男3*（1．广州中医药大学 第五临床医学院，广东 广州 510405；2．广东省中医药工程技术研究院 广东省中医药研究开发重点实验室，广东 广州 510095；3．广州新华学院 药学院，广东 广州 510520）摘要：应用超高效液相色谱-四极杆-飞行时间串联质谱（UPLC-Q-TOF-MS/MS ）技术定性鉴别鸡血藤中药复方提取物的化学成分。
采用Waters ACQUITY UPLC BEH C 18色谱柱（100 mm×2.1 mm ，1.7 µm ），以0.1%甲酸水溶液-乙腈为流动相进行梯度洗脱，电喷雾离子源正、负离子模式扫描。
通过质谱数据库、化合物裂解规律，并结合相关文献进行鉴别。
共鉴别出82种化合物，以黄酮类、苯丙素类、萜类化合物为主，包括黄酮类22种、苯丙素类24种、萜类25种、酚酸类4种、甾体类6种、氨基酸类1种，各药材组成复方后首次发现的新化学成分有10种。
UPLC-Q-TOF-MS/MS 技术为鉴别鸡血藤中药复方中化学成分提供了简便、快速、准确的方法，鉴定得到的各个化学成分涵盖了组方中各味药材的主要成分，可为该复方的质量标准及药效物质研究提供实验依据和理论基础。
关键词：UPLC-Q-TOF-MS/MS ；鸡血藤中药复方提取物；化学成分；裂解规律中图分类号：O657.63；R282.6文献标识码：A 文章编号：1004-4957（2024）04-0511-12Analysis of Chemical Constituents in Jixueteng Formula Extract byUPLC-Q-TOF-MS/MSXIE Can -hui 1，JIA De -zheng 1，XU Ai -li 2，WU Min -shan 1，XIAO Guan -lin 2，BI Xiao -li 2，ZHANG Su -zhong 3，CAO Ying -nan 3*（1．School of the Fifth Clinical Medicine ，Guangzhou University of Chinese Medicine ，Guangzhou 510405，China ；2．Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine ，Guangdong Provincial Engineering Technology Research Institute of T.C.M.，Guangzhou 510095，China ；3．School of Pharmcy of Guangzhou Xinhua University ，Guangzhou 510520，China ）Abstract ：The chemical components of the Jixueteng formula extract were qualitatively identified us⁃ing ultra -high performance liquid chromatography-quadrupole time -of -flight tandem mass spectrome⁃try （UPLC-Q-TOF-MS/MS ） technology. A Waters ACQUITY UPLC BEH C 18 chromatographic col⁃umn （100 mm×2.1 mm ，1.7 µm ） was employed ，with a mobile phase consisting of 0.1% formic ac⁃id solution-acetonitrile using a gradient elution. The flow rate was set at 0.3 mL/min and the column temperature at 30 ℃. MS analysis was based on electrospray ion source with positive and negative ion mode scanning. The identification of compounds was conducted through the mass spectrometry data⁃base ，compound fragmentation patterns ，and relevant literature. In this experiment ，a total of 82 compounds were identified ，mainly including flavonoids ，phenylpropanoids ，and terpenoids. Among them ，there were 22 types of flavonoids ，24 types of phenylpropanoids ，25 types of terpe⁃noids ，4 types of phenolic acids ，6 types of steroids ，and 1 type of amino acids. Additionally ，10 new chemical components were discovered for the first time when the herbal ingredients were com⁃bined to form a compound. UPLC-Q-TOF-MS/MS technology provides a convenient ，fast ，and ac⁃curate method for identifying chemical components in the Jixueteng formula extract. The identifieddoi ：10.12452/j.fxcsxb.23120738收稿日期：2023－12－07；修回日期：2024－01－31基金项目：2021年度广东省重点建设学科科研能力提升项目（2021ZDJS143）；2021年省属科研机构稳定性支持项目（粤财科教［2021］113号）；广州市科技计划项目（202102080588）∗ 通讯作者：曹颖男，博士，教授，研究方向：中药药理学，E -mail ：85394092@研究报告512分析测试学报第 43 卷chemical constituents can cover the main active ingredients of the herbal compound，providing exper⁃imental evidence and theoretical foundation for quality standardization and pharmacological researchof the compound.Key words：UPLC-Q-TOF-MS/MS；Jixueteng formula extract；chemical constituents；fragmen⁃tation pattern近年来癌症的发病率逐年上升，肿瘤的发生发展与机体的免疫功能低下密切相关。
超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物
第42 卷第 11 期2023 年11 月Vol.42 No.111469~1478分析测试学报FENXI CESHI XUEBAO（Journal of Instrumental Analysis）超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物汪毅1，梁文耀1，何国山1，陈张好2，周智明2，吴谦1，席绍峰1，谭建华1*（1．广州质量监督检测研究院，国家化妆品质量检验检测中心（广州），广东广州511447；2．广东省药品检验所，广东广州510663）摘要：采用超高效液相色谱-串联质谱（UPLC-MS/MS）建立了化妆品中15种痕量N-亚硝胺化合物的分析方法。
水剂样品以水或乙腈分组超声提取，膏霜乳液样品采用亚铁氰化钾-乙酸锌溶液沉淀大分子或者饱和氯化钠-乙腈盐析分组处理后，以Agilent Poroshell 120 SB-Aq（100 mm×3.0 mm，2.7 μm）色谱柱分离，经大气压化学电离源（APCI）电离，多反应监测模式检测，以同位素内标法定量。
结果表明，15种N-亚硝胺化合物在相应质量浓度范围内线性关系良好（r2＞0.995），检出限和定量下限分别为5~15 ng/g和15~45 ng/g。
水、乳、膏霜3种化妆品基质在25、50、100 ng/g加标水平下的平均回收率为88.0%~111%，相对标准偏差（RSD，n=6）为1.4%~9.8%。
该方法用于市售化妆品检测，发现13批次样品检出N-亚硝基二乙醇胺（NDELA），其中1批次超限量值。
方法的专属性强，灵敏度高，精密度好，解决了N-亚硝胺化合物稳定性差、易被干扰等问题，适用于化妆品中15种N-亚硝胺化合物的痕量测定。
关键词：N-亚硝胺化合物；化妆品；超高效液相色谱-串联质谱法（UPLC-MS/MS）；大气压化学电离源中图分类号：O657.63；O623.732文献标识码：A 文章编号：1004-4957（2023）11-1469-10 Determination of Fifteen N-nitrosamine Compounds in Cosmetics by Ultra Performance Liquid Chromatography-TandemMass SpectrometryWANG Yi1，LIANG Wen-yao1，HE Guo-shan1，CHEN Zhang-hao2，ZHOU Zhi-ming2，WU Qian1，XI Shao-feng1，TAN Jian-hua1*（1．Guangzhou Quality Supervision and Testing Institute，National Quality Supervision and Testing Center for Cosmetics（Guangzhou），Guangzhou 511447，China；2．Guangdong Institute for Drug Control，Guangzhou 510663）Abstract：An ultra performance liquid chromatography-tandem mass spectrometric（UPLC-MS/MS）method was established for detecting 15 trace N-nitrosamine compounds in cosmetics. The final estab⁃lished method involved ultrasonic extraction of cosmetics using water or acetonitrile for different com⁃pounds. The samples were treated with potassium ferrocyanide-zinc acetate solution for precipitating macromolecules or saturated sodium chloride-acetonitrile for salting out.An Agilent Poroshell 120 SB-Aq（100 mm × 3.0 mm，2.7 μm） chromatography column was used for separation，followed by atmospheric pressure chemical ionization（APCI） source and multiple reaction monitoring mode detec⁃tion in the isotope internal standard method for quantification. The result showed good linearity（r2> 0.995） for the 15 N-nitrosamine compounds in their respective concentration ranges，with detection and quantitation limits of 5-15 ng/g and 15-45 ng/g，respectively.The average recoveries for the three cosmetic matrices（aqueous，emulsion，cream） at spiked levels of 25，50，100 ng/g were be⁃tween 88.0% and 111%，with relative standard deviations（RSD，n=6） of 1.4%-9.8%. The method was applied to the detection of commercial cosmetics and N-nitrosodiethanolamine（NDELA） was de⁃tected in 13 batches，with one batch exceeding the limit. The strong specificity，high sensitivity，and good precision made the method could solve the problems of poor stability and easy interference ofdoi：10.19969/j.fxcsxb.23051602收稿日期：2023－05－16；修回日期：2023－06－10基金项目：广东省药品监督管理局化妆品风险评估重点实验室专项（2021ZDZ03）；广东省市场监督管理局科技项目（2022CZ06）∗通讯作者：谭建华，博士，正高级工程师，研究方向：色谱－质谱检测技术研究，E-mail：tanjianhua0734@第 42 卷分析测试学报N-nitrosamine compounds，and was suitable for the trace determination of 15 N-nitrosamine com⁃pounds in cosmetics.Key words：N-nitrosamine compounds；cosmetics；ultra performance liquid chromatography-tan⁃dem mass spectrometry（UPLC-MS/MS）；atmospheric pressure chemical ionization（APCI） sourceN-亚硝胺化合物是一类具有N-亚硝基结构的化合物，因取代基的不同，形成了种类繁多的同系物，目前已发现超过300种［1］。
加速溶剂萃取-超高效液相色谱-串联质谱法测定大枣中3种五环三萜酸
食品与药品Food and Drug2021年第23卷第1期17加速溶剂萃取-超高效液相色谱-串联质谱法测定大枣中3种五环三祜酸张萍，何婷，王颖，胡克特，顾丁，陈荣祥**(遵义医科大学基础医学院，贵州遵义563000)摘要：目的建立加速溶剂萃取-超高效液相色谱-串联质谱法(ASE-UPLC-MS/MS)同时测定大枣中桦木酸、齐墩果酸和熊果酸的方法。
方法样品釆用ASE提取，优化提取条件，并与超声辅助提取法进行比较。
优化 后的提取条件为：以80%甲醇为提取溶剂，提取温度100-C,静态萃取时间15min,萃取1次。
提取液釆用Waters ACQUITY BEH C18色谱柱分离，以乙ffi-15mmol/L乙酸钱(pH9.3)为流动相，梯度洗脱，经UPLC-MSZMS仪，釆用电喷雾电离源，负离子模式下多反应监测模式检测。
结果桦木酸、齐墩果酸、熊果酸在0.5~10 mg/L范围内，浓度与峰面积线性关系良好，相关系数大于0.9900。
不同浓度3种化合物的加标回收率93.6%〜101.7%,相对标准偏差在1.18%~6.83%之间。
结论此法简单快速、准确稳定、重复性好，可用于大枣中桦木酸、齐墩果酸、熊果酸的含量测定。
关键词：加速溶剂萃取；超高效液相色谱；串联质谱法；大枣中图分类号：R284.1文献标识码：A文章编号：1672-979X(2021)01-0017-06DOI：10.3969/j.issn.l672-979X.2021.01.004Simultaneous Determination of Three Pentacyclic Triterpenic Acids in Jujubae Fructus byAccelerated Solvent Extraction-UPLC-MS/MSZHANG Ping,HE Ting,WANG Ying,HU Ke-te,GU Ding,CHEN Rong-xiang(School of B asic Medical Sciences,Zunyi Medical University,Zu^yi563000,China)Abstract:Objective To establish a method for the simultaneous determination of betulinic acid,oleanolic acid and ursolic acid in Jujubae fructus by ultra-high performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS)with accelerated solvent extraction(ASE).Methods The extract parameters of A SE were optimized and the efficiency was compared with the ultrasound-assisted extraction method.The optimum extraction conditions were as follows:80%methanol was selected as extraction solvent,oven temperature was100°C,the static extraction time was 15min and one extraction cycle was adopted.A waters ACQUITY BEH C18(2.1mmx]00mn,1.7“m)column was used as the stationary phase,acetonitrile and ammonium acetate solution(15mmol/L,pH9.3)was used as the mobile phase.Mass detection was conducted by electrospray ionization in negative ion multiple reaction monitoring mode. Results The calibration curves were linear over a concentration range of0.5-10mg/L for betulinic acid,oleanolic acid and ursolic acid.The correlation coefficients were greater than0.9900.The recoveries of different spiked levels were between93.6%and101.7%,with RSDs between1.18%and6.83%.Conclusion The method is simple,rapid,收稿日期：2020-09-04基金项目：国家自然科学基金(31660131,81760652)；贵州省联合基金(黔科合J字LKZ[2013]17号)；遵义医学院博士启动基金(F-568)作者简介：张萍，硕士研究生，研究方向：药用植物开发与利用E-mail:******************通讯作者：陈荣祥，教授，博士，研究方向：药用植物开发与利用E-mail:*************************18食品与药品Food and Drug2021年第23卷第1期accurate,stable and reproducible.It can be used for the determination of betulinic acid,oleanolic acid and ursolic acid in Jujubae f ructus.Key Words:accelerated solvent extraction;ultra-high performance liquid chromatography;tandem mass spectrometry; Jujubae f ructus.大枣为鼠李科植物枣树（Ziziphus jujuba Mill.）的干燥成熟果实，不仅作为食物，还是传统中医药中的常用药材。
XMD8-92_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:XMD8–92 is a highly selective ERK5/BMK1 inhibitor with dissociation constant (K d ) value of 80 nM.IC50 & Target: Kd: 80 nM (ERK5/BMK1)[1]In Vitro: XMD8–92 exhibits the greatest affinity towards BMK1 with a measured dissociation constant (K d ) of 80 nM, while DCAMKL2, TNK1 and PLK4 exhibit K d ’s of 190, 890 and 600 nM, respectively. XMD8–92 is profiled against all detectable kinases in HeLa cell lysates using the KiNativ method and is found to be about 10–fold more selective for BMK1 with a IC 50 of 1.5 μM than the most potent off–targets, TNK1 (IC 50=10 μM) and ACK1 (aka TNK2, IC 50=18 μM). Other weak off–targets include the kinasedomain 2 of RSK1 and RSK2, PIK4A and PIK4B, and FAK. Notably, MEK5 is not significantly inhibited by XMD8–92 at up to 50 μM [1].XMD8–92 shows high selectivity to BMK1 in an in vitro ATP–site competition binding assay against 402 kinases as well as in the KiNativ method against all detectable kinases in HeLa cell lysates. XMD8–92 blocks EGF–induced activation of BMK1 with IC 50 of 240 nM and, with concentration as high as 5 μM, XMD8–92 has no inhibitory effect on ERK1/2 activation by EGF [2].In Vivo: XMD8–92 significantly inhibits tumor growth in vivo by 95%. The pharmacokinetics of XMD8–92 is evaluated inSprague–Dawley rats given a single intravenous or oral dose. XMD8–92 is found to have a 2.0 hr half life clearance of 26mL/min/kg. XMD8–92 has moderate tissue distribution with a calculated volume of distribution of 3.4 L/kg. XMD8–92 has high oral bioavailability with 69% of the dose absorbed. After a single oral dose of 2 mg/kg, maximal plasma concentrations ofapproximately 500 nM are observed by 30 minutes, with 34 nM remaining 8 hr post dose. In tolerability experiments, high plasma concentrations of drug (approximately 10 μM following IP dosing of 50 mg/kg) are maintained throughout the 14 days. XMD8–92appeares to be well tolerated and the mice appeared healthy with no sign of distress. No vasculature instability is observed in the XMD8–92–treated mice [1]. XMD8–92 treatment in both immunocompetent and immunodeficient mice blocked the growth of lung and cervical xenograft tumors, respectively, by 95%. This remarkable anti–tumor effect of XMD8–92 in lung and cervical xenograft tumor models is due to XMD8–92’s capacity to inhibit tumor cell proliferation through the PML suppression–inducted p21checkpoint protein, and by blocking of BMK1’s contribution in tumor–associated angiogenesis. Besides, BMK1 knockout (KO) in mice leads to complete and irreversible removal of the BMK1 protein, while XMD8–92 treatment in mice only suppresses the activity of BMK1, which is reversible. Second, the vasculature instability observed in BMK1 KO mice may be due to lack of the C–terminal non–kinase domain of BMK1, which is still present during XMD8–92 treatment of animals [2].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]KiNativ profiling of XMD8–92 is carried out with both an ATP and ADP acylphosphate–desthiobiotin with the following modifications. HeLa cell lysates (5 mg/mL total protein) are incubated in the presence of XMD8–92 at 50 μM, 10 μM, 2μM, 0.8 μM, and 0 μM for 15 minutes prior to addition of the ATP or ADP acylphosphate probe (5 μM final probe concentration). All reactions are performed in duplicate. Probe reactions proceeded for 10 minutes and the reaction stopped by the addition of urea and processed for MS analysis. Samples are analyzed by LC–MS/MS on a linear ion trap mass spectrometer using a time segmentedProduct Name:XMD8–92Cat. No.:HY-14443CAS No.:1234480-50-2Molecular Formula:C 26H 30N 6O 3Molecular Weight:474.55Target:ERK; ERK Pathway:Stem Cell/Wnt; MAPK/ERK Pathway Solubility:10 mM in DMSO“target list” designed to collect MS/MS spectra from all kinase peptide–probe conjugates that can be detected in HeLa cell lysates. This target list is generated and validated by prior exhaustive analysis of HeLa lysates. Up to four characteristic fragment ions for each kinase peptide–probe conjugate are used to extract signals for each kinase, and a comparison of inhibitor treated to control (untreated) lysates allow for precise determination of % inhibition at each point. A manuscript describing the details of this targeted mass spectrometry approach is in preparation[1].Animal Administration:[1]Mice[1]5×105 HeLa cells are resuspended in DMEM and injected subcutaneously into the right flank of 6–week–old Nod/Scid mice (day 0). On the second day (day 1) after tumor cell injection, mice are randomized into 2 groups (6 animals, XMD8–92, 1–28 day, and 18 animals, control). The XMD8–92 (1–28 day) group is treated with XMD8–92 at the dose of 50 mg/kg twice a day intraperitoneally. The control group receive daily injections of the carrier solution as control. On the day 7, the control group is randomized into 2 groups (6 animals, XMD8–92, 7–28 day, and 12 animals, control). And on the day 14, the remaining control group is randomized into 2 groups (6 animals, XMD8–92, 14–28 day, and 6 animals, control). Treatment with XMD8–92 inXMD8–92 (7–28 day) and XMD8–92 (14–28 day) groups is initiated on day 7 and day 14, respectively. Tumor size is measured using a caliper, and tumor volume is determined by using the formula: L×W2×0.52, where L is the longest diameter and W is the shortest diameter.References:[1]. Yang Q, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.Cancer Cell. 2010 Sep 14;18(3):258–67.[2]. Yang Q, et al. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 2011 Jun 1;17(11):3527–32.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Name:
A 922500CAS No.:
959122-11-3Cat. No.:
HY-10038
Product Data Sheet
MWt:
428.48Formula:
C26H24N2O4Purity :>98%
Solubility:
DMSO 86 mg/ml; Water < 1 mg/ml
Mechanisms:
Biological Activity:
A 922500is a potent selective and orally bioavailable DGAT 1inhibitor with IC50values of 7nM Pathways:Metabolism/Protease; Target:DGAT A 922500 is a potent, selective, and orally bioavailable DGAT-1 inhibitor with IC50 values of 7 nM
and 24 nM for human and mouse DGAT-1 respectively.
IC50 Value: 7 nM(human DGAT-1); 24 nM(DGAT-1) [1]
Target: DGAT-1in vitro: A 922500 potently inhibits huDGAT-1 and mseDGAT-1 [1]. A 922500 inhibits the
phylogenetic family members acyl coenzyme A cholesterol acyltransferase-1 and -2 with IC50 of 296
μM [2]. in vivo: Zucker fatty rats and diet-induced dyslipidemic hamsters were dosed orally with A-922500(0.03, 0.3, and 3-mg/kg), a potent and selective DGAT-1 inhibitor, for 14 days. Serum triglycerides References:
[1]. Zhao, Gang; Souers, Andrew J.; Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor . Journal of Medicinal Chemistry (2008), 51(3), 380-383.(g g)p y g y
were significantly reduced by the 3 mg/kg dose of the DGAT-1 inhibitor in both the Zucker fatty rat (39%) and hyperlipidemic hamster (53%) [1]. A 922500 confers weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depletes serum trigly...
y (),(),[2]. King, Andrew J.; Segreti, Jason A.; Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. Journal of Pharmacology and
Experimental Therapeutics (2009), 330(2), 526-531.[3]. King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Collins CA, Voorbach MJ, Zhao G, Mittelstadt SW, Cox BF.In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1inhibition in rodent models of postprandial hyperlipidemia.Eur J Pharmacol. 2010 Jul 10;637(1-
3):155-61. Epub 2010 Apr 10....
Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。